ES2090332T3 - Tejido linfoide humano en un hospedador inmunocomprometido. - Google Patents

Tejido linfoide humano en un hospedador inmunocomprometido.

Info

Publication number
ES2090332T3
ES2090332T3 ES91909374T ES91909374T ES2090332T3 ES 2090332 T3 ES2090332 T3 ES 2090332T3 ES 91909374 T ES91909374 T ES 91909374T ES 91909374 T ES91909374 T ES 91909374T ES 2090332 T3 ES2090332 T3 ES 2090332T3
Authority
ES
Spain
Prior art keywords
lymphoid tissue
immunocommitted
hospital
human
human lymphoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91909374T
Other languages
English (en)
Inventor
Susan Mayo
Reiko Namikawa
Hideto Kaneshima
Joseph M Mccune
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Systemix Inc
Original Assignee
Systemix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Systemix Inc filed Critical Systemix Inc
Application granted granted Critical
Publication of ES2090332T3 publication Critical patent/ES2090332T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Environmental Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Surgical Instruments (AREA)
  • Peptides Or Proteins (AREA)

Abstract

EL TEJIDO LINFOIDE HUMANO SE INTRODUCE EN UN HUESPED INMUNOCOMPROMETIDO PARA DAR LA OPORTUNIDAD DE INVESTIGAR EL EFECTO DE ESTIMULOS EN EL SISTEMA INMUNOLOGICO HUMANO Y OBTENER INFORMACION Y PRODUCTOS PARA EL ESTIMULO. SE PRESENTA, DE MANERA PARTICULAR, LA METODOLOGIA PARA LA PRODUCCION DE ANTICUERPOS MONOCLONALES HUMANOS MEDIANTE LA INTRODUCCION DE TEJIDO LINFOIDE EN UN HUESPED INMUNOCOMPROMETIDO, ESTIMULANDO LOS LINFOCITOS B CON UN INMUNOGEN APROPIADO, RECOGIENDO EL TEJIDO E INMORTALIZANDO Y/O CLONANDO LOS LINFOCITOS B BAJO CONDICIONES CAPACES DE PROPORCIONAR UN SUMINISTRO ESTABLE DE ANTICUERPOS MONOCLONALES.
ES91909374T 1990-05-03 1991-04-29 Tejido linfoide humano en un hospedador inmunocomprometido. Expired - Lifetime ES2090332T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51874890A 1990-05-03 1990-05-03

Publications (1)

Publication Number Publication Date
ES2090332T3 true ES2090332T3 (es) 1996-10-16

Family

ID=24065324

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91909374T Expired - Lifetime ES2090332T3 (es) 1990-05-03 1991-04-29 Tejido linfoide humano en un hospedador inmunocomprometido.

Country Status (11)

Country Link
US (1) US5411749A (es)
EP (1) EP0481058B1 (es)
JP (1) JPH04507109A (es)
AT (1) ATE140480T1 (es)
AU (1) AU637914B2 (es)
CA (1) CA2063408A1 (es)
DE (1) DE69120890T2 (es)
DK (1) DK0481058T3 (es)
ES (1) ES2090332T3 (es)
GR (1) GR3021382T3 (es)
WO (1) WO1991016910A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652373A (en) * 1990-01-15 1997-07-29 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
US5849288A (en) * 1990-01-15 1998-12-15 Yeda Research And Development Co. Ltd. Method for production of monoclonal antibodies in chimeric mice or rats having xenogeneic antibody-producing cells
DK9091D0 (da) * 1991-01-18 1991-01-18 Novo Nordisk As Fremgangsmaade til fremstilling af antistoffer
US5849987A (en) * 1992-06-02 1998-12-15 Yeda Research And Development Co. Ltd. Animal model for hepatitis virus infection
US5804160A (en) * 1991-06-04 1998-09-08 Yeda Research And Development Co. Ltd Animal model for hepatitis virus infection
US5858328A (en) * 1991-06-04 1999-01-12 Yeda Research And Development Co. Ltd. Animal model for hepatitis virus infection
EP0539970B1 (en) * 1991-10-30 1999-05-26 Idemitsu Kosan Company Limited Methods for producing human lymphocytes and human monoclonal antibodies, and human monoclonal antibodies produced thereby
US5866757A (en) * 1992-06-02 1999-02-02 Yeda Research And Development Co. Ltd. Engraftment and development of xenogeneic cells in normal mammals having reconstituted hematopoetic deficient immune systems
JP2801085B2 (ja) * 1992-09-11 1998-09-21 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン ヒト細胞を植えた気道上の異種移植片を有する非ヒト動物
US5663481A (en) * 1993-08-06 1997-09-02 Mount Sinai Hospital Corporation Animal model of the human immune system
US5645982A (en) * 1993-08-19 1997-07-08 Systemix, Inc. Method for screening potential therapeutically effective antiviral agents
US5516977A (en) * 1993-12-17 1996-05-14 Systemix, Inc. Xenogeneic tissue implant in ear pinna
US6455756B1 (en) * 1994-08-12 2002-09-24 Novartis Ag Long term xenogeneic myeloid and lymphoid cell production in chimeric immunocompromised mice
EP0792294A1 (en) * 1994-11-16 1997-09-03 Baxter International Inc. Human antibodies to t-cell receptor peptides and methods for their preparation
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US20020182730A1 (en) * 1995-07-26 2002-12-05 Micheal L. Gruenberg Autologous immune cell therapy: cell compositions, methods and applications to treatment of human disease
US5986170A (en) * 1995-11-13 1999-11-16 Corixa Corporation Murine model for human carcinoma
IL132164A0 (en) * 1997-04-09 2001-03-19 Chang Lung Ji Animal model for evaluation of vaccines
EP2289550A3 (en) * 2000-01-27 2012-02-15 MedImmune, LLC Ultra high affinity neutralizing antibodies
DK1259547T3 (da) 2000-03-01 2012-10-15 Medimmune Inc Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
FR2821947B1 (fr) * 2001-03-12 2003-05-16 Canon Kk Procede et dispositif de validation de parametres definissant une image
US20030134415A1 (en) * 2001-09-19 2003-07-17 Gruenberg Micheal L. Th1 cell adoptive immunotherapy
US20030134341A1 (en) * 2001-09-19 2003-07-17 Medcell Biologics, Llc. Th1 cell adoptive immunotherapy
US20030175272A1 (en) * 2002-03-07 2003-09-18 Medcell Biologics, Inc. Re-activated T-cells for adoptive immunotherapy
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
WO2005004794A2 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
WO2006050166A2 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US20090291073A1 (en) * 2008-05-20 2009-11-26 Ward Keith W Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
EP4502152A3 (en) 2009-10-06 2025-04-30 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
US20110229921A1 (en) * 2010-03-18 2011-09-22 Abbott Laboratories METHODS OF ASSAYING URINARY NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN (uNGAL) IN THE PROGNOSIS OF CADAVERIC KIDNEY TRANSPLANT FUNCTION IN A PATIENT, INCLUDING A PATIENT DIAGNOSED WITH DELAYED GRAFT FUNCTION (DGF), A METHOD OF ASSAYING uNGAL IN THE ASSESSMENT OF RISK OF DGF IN A PATIENT DIAGNOSED WITH EARLY GRAFT FUNCTION (EGF), AND RELATED KITS
US9551714B2 (en) 2010-06-25 2017-01-24 Abbott Laboratories Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
SG10202008003VA (en) 2011-02-15 2020-10-29 Regeneron Pharma Humanized m-csf mice
US8993248B2 (en) 2011-12-31 2015-03-31 Abbott Laboratories Truncated human vitamin D binding protein and mutation and fusion thereof and related materials and methods of use
FI2892330T3 (fi) 2012-09-07 2023-03-25 Univ Yale Geneettisesti muokattuja hiiriä ja menetelmiä niiden käyttämiseksi
MX377561B (es) 2012-11-05 2025-03-10 Regeneron Pharma Animales no humanos genéticamente modificados y métodos de uso de los mismos.
MX2016014995A (es) 2014-05-19 2017-03-31 Regeneron Pharma Animales no humanos geneticamente modificados que expresan eritropoyetina de humano.
ES2950399T3 (es) 2015-04-13 2023-10-09 Regeneron Pharma Ratones humanizados Sirpa-IL15 insertados y métodos de uso de los mismos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3853201T2 (de) * 1987-12-23 1995-09-14 Univ Leland Stanford Junior Schimäre immunkompromittierende Säugetiere und ihre Verwendung.
JP2981486B2 (ja) * 1988-06-14 1999-11-22 メディカル・バイオロジー・インスティチュート 哺乳動物の免疫系研究方法
DK0438053T3 (da) * 1990-01-15 1999-11-22 Yeda Res & Dev Varig transplantation og udvikling af humane hæmopoietiske cellelinjer i normale pattedyr
WO1991018615A1 (en) * 1990-05-25 1991-12-12 Systemix, Inc. Human peripheral blood cells in an immunocompromised host
JPH04252128A (ja) * 1990-08-03 1992-09-08 Systemix Inc 免疫化された宿主における変性された異種移植器官系

Also Published As

Publication number Publication date
WO1991016910A1 (en) 1991-11-14
AU7858391A (en) 1991-11-27
EP0481058B1 (en) 1996-07-17
ATE140480T1 (de) 1996-08-15
DE69120890D1 (de) 1996-08-22
DE69120890T2 (de) 1997-02-20
DK0481058T3 (da) 1996-12-02
EP0481058A4 (en) 1993-07-14
JPH04507109A (ja) 1992-12-10
US5411749A (en) 1995-05-02
EP0481058A1 (en) 1992-04-22
AU637914B2 (en) 1993-06-10
GR3021382T3 (en) 1997-01-31
CA2063408A1 (en) 1991-11-04

Similar Documents

Publication Publication Date Title
ES2090332T3 (es) Tejido linfoide humano en un hospedador inmunocomprometido.
DE69031120D1 (de) Her2 extrazellulare domäne
DK0714444T3 (da) Dæmpning af en immundominant epitop i et antigen til anvendelse i plante-, dyre- og humanvacciner og immunbehandlinger
DE68924162D1 (de) Stressproteine und verwendungen dafür.
DE69329503D1 (de) Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
ATE246513T1 (de) Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
ATE154642T1 (de) Monoklonale antikörper gegen das mikrotubulusassoziierte protein tau.
ES2145004T3 (es) Derivados de anticuerpos.
ATE4770T1 (de) Herstellung von produkten fuer den menschlichen oder tierischen konsum unter verwendung eines saccharose-ersatzstoffes.
ATE319474T1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
GB2277270A (en) Electrophysiological conditioning system and method
DE69334259D1 (de) Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierungs-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyten beschränkt ist, für die Behandlung von B-Zell-Lymphoma
NO933126D0 (no) Loeselige ligander for cd40
ATE127694T1 (de) Lebende impfstoffe.
DE68927438D1 (de) Verfahren zur herstellung monoklonaler antikörper mit hilfe eines keimfreien tieres
ATE237351T1 (de) Mit staphylococcus epidermidis assoziierte oberflächenantigene des typs i
NO934851L (no) Fremgangsmåte for stimulering av immunrespons
EP0570583A4 (en) ACTIVE SUBSTANCE FOR HAIR MODIFICATION AND HAIR CARE PRODUCT, WHICH CONTAIN BOTH AN ANTI-KERATINE ANTIBODY, AND PRODUCTION OF THE ANTI-KERATINE ANTIBODY.
EP0668772A4 (en) SPECIFIC MODULATIONS OF THE IMMUNE SYSTEM.
DE3789082D1 (de) Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors.
NZ210867A (en) Tumour-specific monoclonal antibodies, production thereof and use
NZ216119A (en) Vaccine produced using antigens of a pseudocapsule producing strain of s.aureus
NO913078D0 (no) Oekt proteinproduksjon i dyr.
GR3021983T3 (en) Cross-reactive influenza a immunization
Umnyashkin Experience of neuroleptic-resistant schizophrenia treatment

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 481058

Country of ref document: ES

FG2A Definitive protection

Ref document number: 481058

Country of ref document: ES